METHODS FOR TREATING TREATMENT-NAIVE AS WELL AS TREATMENT-EXPERIENCED PATIENTS HAVING RCC TO ACHIEVE AT LEAST A PARTIAL TUMOR RESPONSE INVOLVING ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF PEGYLATED INTERFERON-ALFA, E.G., PEGYLATED INTERFERON ALFA-2B AS MONOTHERAPY OR IN ASSOCIATION WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF IL-2 ARE DISCLOSED.